L01XX02 • asparaginase • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Asparaginase is a medication used in the treatment of acute lymphoblastic leukemia (ALL), particularly in children but also in adults. It is an enzyme that breaks down asparagine, an amino acid essential for the growth and survival of cancer cells. Since cancer cells cannot produce asparagine, the lack of this amino acid causes their death, while normal cells are less affected.
Asparaginase is usually administered via intramuscular or intravenous injection as part of a combination chemotherapy regimen. The dosage and frequency of administration are determined by the doctor based on the patient's age, weight, and overall condition.
Common side effects include allergic reactions (such as rashes, itching, or difficulty breathing), nausea, vomiting, fatigue, increased blood sugar levels, and impaired liver or pancreatic function. In rare cases, it may cause severe reactions, such as blood clotting issues or pancreatitis.
Asparaginase is a critical medication in the treatment of acute lymphoblastic leukemia, but its use requires close monitoring by the medical team to manage potential side effects and ensure the effectiveness of the therapy.
Substance: asparaginase
Date of last drug list: 01-12-2021
Commercial code: W64915001
Concentration: 10000 U / vial
Pharmaceutical form: powder for injection / infusion solution
Quantity: 5
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: PORTON BIOPHARMA LIMITED - MAREA BRITANIE
Holder: DIRECT PHARMA LOGISTICS S.R.L. - ROMANIA
Number: 497/2020/01
Shelf life: 3 years